Affiliation:
1. Sechenov First Moscow State Medical University (Sechenov University)
2. Stavropol State Medical University
3. St Petersburg University
4. Lotus Medical Center
5. Russian Scientific Center of Radiology and Surgical Technologies named after academician A.M. Granov
6. PolyClinic “EXPERT”
7. SM-clinic
Abstract
Introduction. The increase in serum transaminases (ALT and AST) and the persistence of their high values is associated with morbidity and mortality from liver diseases. Bicyclol has anti-inflammatory and antioxidant effects, which formed the basis for this study.Materials and methods. The study enrolled 51 patients (MELD < 19); hepatitis stage – 84.4%, cirrhosis – 15.6%. Treatment: Bicyclol 75 mg/day for 12 weeks. Criteria of efficacy: dynamics of ALT, AST, CRP; general well-being (D-FIS scale).Results. After 4 weeks of treatment the share of patients with ALT normalization was 50,9% (p < 0,001); with AST normalization – 62.7% (p < 0.001); after 12 weeks - 79,5% and 89,7% respectively (p < 0,001). CRP decreased statistically significantly after 2 and 4 weeks from the beginning of treatment. The D-FIS questionnaire was filled in by 36 patients at the beginning of the study, in 4 weeks - by 35 patients, in 12 weeks – by 32 patients. Median D-FIS decreased from 12 (8.2; 32.2) to 8 (5; 29) points (p < 0,001) after 4 weeks of treatment, after 12 weeks – to 6.5 (3; 28.5) points (p < 0.001). The CRP was positively correlated with the D-FIS value. Fibrosis (“Fibromax”, “Fibroscan”) was studied in 10 additional patients, the dose of Bicyclol was 150/75 mg/day during 6 months, the result was statistically significant (p < 0.001).Conclusion. Application of Bicyclol leads to reduction of fatigue, local and systemic inflammation, fibrosis in chronic diffuse liver diseases regardless of etiology.
Reference22 articles.
1. Ivashkin V.T., Mayevskaya M.V., Zharkova M.S., Tikhonov I.N., Fedosina E.A., Pavlov CH.S. Algorithms of diagnostics and treatment in hepatology. Moscow: MEDpress-Inform; 2016. 176 p. (In Russ.) Available at: https://www.rsls.ru/files/news/Present2208.pdf.
2. Kwo P.U., Cohen S.M., Lim J.K. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18–35. doi: 10.1038/ajg.2016.517.
3. Ruhl C.E., Everhart J.E. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology. 2012;55(2):447–454. doi: 10.1002/hep.24725.
4. Arndt V., Brenner H., Rothenbacher D., Zschenderlein B., Fraisse E., Fliedner T.M. Elevated liver enzyme activity in construction workers: prevalence and impact on early retirement and all-cause mortality. Int Arch Occup Environ Health. 1998;71:405–412. doi: 10.1007/s004200050299.
5. Chang Kim Hyeon, Mo Nam Chung, Ha Jee Sun, Hyub Han Kwang, Dae Kyu Oh, Il Suh. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:983. doi: 10.1136/bmj.38050.593634.63.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献